# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients

> **NCT06385964** · PHASE1 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 62 (actual)

## Conditions studied

- Healthy Subjects
- Asthmatic Patients

## Interventions

- **DRUG:** SHR-4597
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06385964
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-07
- **Primary completion:** 2025-02-19
- **Final completion:** 2025-02-19
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385964, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06385964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*